Telitacicept for low platelets from connective tissue disease
Treatments studied
Part of Blood & lymphatic, Skin clinical trials.
This trial tests a new medicine called telitacicept for people with connective tissue disease (like lupus or Sjögren's) whose platelet counts stay dangerously low despite standard treatments. It aims to raise platelet levels and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a connective tissue disease (like Sjögren's syndrome, lupus, or undifferentiated connective tissue disease).
- Your platelet count is below 50 × 10^9/L (a low number that can cause bruising or bleeding).
- Your low platelets haven't improved with steroids and at least one other immune-suppressing medicine, or they came back when you tried to lower the steroid dose.
- Your ANA test is positive (a marker of autoimmune activity).
- You are on a stable dose of your current treatments for at least 2 weeks before starting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
This trial tests if a new medication, telitacicept, is safe and effective for people with difficult-to-treat rheumatoid arthritis. It may be an option for patients who have not found relief from other treatments.
This trial tests a new drug called telitacicept for people with lung scarring caused by connective tissue diseases. It aims to see if the drug can improve lung function and slow down the disease progression.
This trial tests a medicine called Telitacicept to see if it can prevent lupus flares in people whose disease is currently mild or stable. It may be a good option if you want to keep your lupus under control and avoid sudden worsening.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
This trial tests a new CAR-T cell treatment called Inaticabtagene Autoleucel for people with lupus that causes very low platelet counts (immune thrombocytopenia) that hasn't gotten better with standard treatments. The goal is to see if it can help raise platelet levels.
Hear when a new Connective Tissue Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.